Abstracts tagged "Bone Resorption"

Abstract Number: 2592 • ACR Convergence 2025
Romosozumab and Denosumab Combination Therapy in Postmenopausal Osteoporosis
Giovanni Adami¹, Francesco Pollastri², Angelo Fassio², Camilla Benini², Davide Gatti², Ombretta Viapiana² and Maurizio Rossini², ¹University of Verona, Italy, Verona, Italy, ²University of Verona, Verona, Italy
Background/Purpose: Transition from long-term denosumab to PTH-analogs or romosozumab might expose patients to the risk of the so-called rebound phenomenon. Adding romosozumab to denosumab might…
Abstract Number: 2120 • ACR Convergence 2025
Analyzing Gender and Racial Disparities in Paget’s Disease of Bone: A Large-Scale Observational Study
Kinga Grzybowski¹, Ahmer Khan² and Arthur Lau³, ¹Jefferson Einstein Montgomery Hospital, Maspeth, NY, ²Jefferson Einstein Philadelphia Hospital, Philadelphia, ³Jefferson Einstein Hospital, Maple Glen, PA
Background/Purpose: Osteitis deformans, commonly referred to as Paget’s Disease of the Bone (PDB), affects adults over the age of 55, mainly of European descent and…
Abstract Number: 2117 • ACR Convergence 2025
Denosumab Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis: A Multi-site Randomized Clinical Trial
Giovanni Adami¹, Kenneth Saag², Gary Cutter³, Rahima Begum³, Elizabeth Dye⁴, Phillip Foster⁵, Camilla Benini⁶, Carmela Dartizio⁶, Davide Gatti⁶ and Maria I. ("Maio") Danila⁷, ¹University of Verona, Italy, Verona, Italy, ²The University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, ⁴UAB, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶University of Verona, Verona, Italy, ⁷University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Prompt anti-resorptive treatment with bisphosphonates after denosumab discontinuation is generally recommended. Glucocorticoid users may not require longer term denosumab and are at greater fracture…
Abstract Number: 1815 • ACR Convergence 2025
New-Onset Juvenile Spondyloarthritis is Characterized by Bone Metabolism Disturbances with Biomarker Potential
Brittney Newby¹, Timothy Brandon¹, Pamela Weiss² and E. John Wherry³, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Childrens Hospital of Philadelphia, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Juvenile spondyloarthritis (JSpA) management is hindered by the lack of reliable biomarkers to predict which patients will develop progressive structural changes, such as erosions…
Abstract Number: 1784 • ACR Convergence 2025
Multimodal Preclinical Screening Of Glucocorticoid-Induced Disruption Of Bone Remodeling In Rat
Anik Tuladhar, Caitlyn Carter, Erin Vaughan, martin j.voorbach, Sabyasachi Biswas, Timothy Brayman, Pankaj Kumar, anastasia marinopoulos, Xin Huang, Sjoerd J. Finnema, Romy Christmann, Terry vanVleet, Brian Enright, Magali Guffroy and Stacey Fossey, AbbVie, North Chicago, IL
Background/Purpose: Bone toxicity during drug development can arise from intended pharmacologic mechanisms or off-target effects. Standard histopathological evaluation often fails to detect early skeletal alterations,…
Abstract Number: 0086 • ACR Convergence 2025
Androgen Upregulates Interferon Signaling in Osteoclast Differentiation During Inflammatory State
Kiana Chen¹, Chia-Lung Wu², Gulzada Kulzhanova² and Homaira Rahimi³, ¹University of Rochester School of Medicine and Dentistry, Bronx, NY, ²University of Rochester Medical Center, Rochester, ³University of Rochester, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) is characterized by chronic inflammatory erosions and female predominant disease. Androgen, the dominant sex hormone in males, is protective against bone…
Abstract Number: 0415 • ACR Convergence 2024
Prevalence and Risk Factors of Low Bone Mineral Density in Children with Juvenile Idiopathic Arthritis
narendra bagri, Sushain Kalsotra, vandana jain, Manisha Jana, Maroof Ahmed Khan, Yashdeep Gupta and Sumit Kumar Das, All India Institute of Medical Sciences, New Delhi, Delhi, India
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatological disease in children less than 16 years of age. Various factors have been suggested…
Abstract Number: 0817 • ACR Convergence 2024
2024 Clinical Practice Guideline for the Diagnosis and Treatment of Chronic Nonbacterial Osteitis (CNO) in Adults
Elizabeth Winter, Olaf Dekkers and Anne Leerling, and the Expert Consensus Panel for Chronic Nonbacterial Osteitis (CNO) in Adults, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Adults with sterile bone inflammation are variably labelled as Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis (SAPHO)-syndrome, chronic nonbacterial osteomyelitis, chronic recurrent multifocal osteomyelitis (CRMO), pustulotic…
Abstract Number: 2102 • ACR Convergence 2024
Unraveling Knee Osteoarthritis Subtypes: Differential Effect of Oral Salmon Calcitonin Treatment
Monica Hannani¹, Peder Frederiksen², Morten Karsdal², Asger Reinstrup Bihlet³, Jaume Bacardit⁴, Anne-Christine Bay-Jensen² and Christian Thudium², ¹Nordic Bioscience & University of Copenhagen, Herlev, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³NBCD A/S, Soeborg, Denmark, ⁴School of Computing, Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Osteoarthritis (OA) patients are to this day left without effective treatment options. Despite different etiologies, trials designs do not account for the substantial heterogeneity…
Abstract Number: 0058 • ACR Convergence 2024
Bradykinin Receptor B1 Blockade Suppresses Soluble CD13-Induced Differentiation of Osteoclasts from Monocytes
Sei Muraoka¹, Qi Wu², Mikel Gurrea-Rubio³, Camila Amarista², William Brodie², Megan Mattichak², Yuzo Ikari⁴, Caroline Foster², Phillip Campbell², David Fox⁵ and Pei-Suen Tsou², ¹University of Michigan, Toyko, Japan, ²University of Michigan, Ann Arbor, MI, ³University of Michigan - Ann Arbor, Ann Arbor, MI, ⁴Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ⁵University of Michigan, Dexter, MI
Background/Purpose: CD13 is an ectopeptidase expressed on myeloid cells, endothelial cells, and rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS). Soluble (s) CD13 is generated by matrix…
Abstract Number: 0267 • ACR Convergence 2024
IL-17 Participates in the Pathogenesis of Chronic Gouty Arthritis
Hong Di¹, Xinxin Han¹, Yun Zhang² and Xuejun Zeng¹, ¹Peking Union Medical College Hospital, Beijing, China, ²Peking Union Medical College Hospital (CAMS), Beijing, China
Background/Purpose: Chronic gouty arthritis (CGA) is different from acute gouty arthritis (AGA), its main characteristics include repeated or even persistent joint symptoms, tophus and bone destruction.…
Abstract Number: 0226 • ACR Convergence 2023
Relationships Among Parameters of Mineral Metabolism and Bone Turnover During Acute COVID-related Hospitalization and Subsequent Follow Up: A Pilot Study
Diego Cabrera¹, Clara Wong², Anna Santoro¹, Christine Simpson¹, Karl Insogna¹, Mary Geda¹, Andrew Cohen¹, Alexandra Hadjuk¹, Lauren Ferrante¹ and Evelyn Hsieh³, ¹Yale School of Medicine, New Haven, CT, ²Yale School of Public Health, New Haven, CT, ³Yale University, Department of Medicine, Section of Rheumatology; Yale School of Public Health; Section of Rheumatology, VA Connecticut Healthcare System, Westport, CT
Background/Purpose: Inflammatory conditions can exert direct adverse effects on bone metabolism, via increased bone resorption with inadequate compensatory bone formation. COVID-19 has been associated with…
Abstract Number: 0881 • ACR Convergence 2023
Deficiency of the Pattern-recognition Receptor CD14 Protects Against LPS-induced Inhibition of Osteoclastogenesis in Vitro
Lance Murphy¹, Kevin Burt², Baofeng Hu³, Vu Nguyen², Robert Mauck² and Carla Scanzello², ¹University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Wynnewood, PA
Background/Purpose: Osteoarthritis is associated with bone changes such as subchondral sclerosis, bone marrow lesions, and osteophyte formation (Donel S, 2019). Prior work has demonstrated that…
Abstract Number: 1185 • ACR Convergence 2023
Soluble Buffered Alendronate After Denosumab Discontinuation in Erosive Hand OA Patients
Tine Vanhaverbeke¹, Dirk Elewaut² and Ruth Wittoek¹, ¹Dept. of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Belgium, ²Ghent University and VIB Center for Inflammation Research, Ghent, Belgium
Background/Purpose: In osteoporotic patients, discontinuation of denosumab is associated with a rapid increase in bone turnover and bone loss. Denosumab was recently proven to have…
Abstract Number: 1300 • ACR Convergence 2023
Bone Marrow Edema in MRI Is More Associated with Rapid Radiographic Progression Than Clinically Relevant Radiographic Progression
Kou Katayama¹, Takanobu Okubo², Toshikazu Sato¹, Kitaru Tanaka³, Tomoki Kawahata³, Yuichi Makino⁴ and Hiroshi Ito⁵, ¹Department of Orthopedic Surgery, Katayama Orthopedic Rheumatology Clinic, Asahikawa, Japan, ²Department of Radiology, Katayama Orthopedic Rheumatology Clinic, Asahikawa, Japan, ³Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan, ⁴Department of Medicine, Division of Rheumatology, Asahikawa Medical University Hospital, Asahikawa, Japan, ⁵Department of orthpedic surgery, Asahikawa Medical University, Asahikawa, Japan
Background/Purpose: Rapid radiographic progression (RRP) is selected as one of the risk factors for difficult- to- treat RA, which needs to be resolved as soon…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].